Mapping the full antigenic landscape of Sjögren's disease using T-Scan technology to identify the drivers of autoimmune T cell responses and enable targeted therapies.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.
Systematically identifying and validating repurposed FDA-approved drugs for over 160 autoimmune diseases using AI, knowledge graphs, and high-throughput experimental screening.
Modernizing anti-nuclear antibody testing by combining AI-enhanced image analysis with multiplex autoantibody profiling to improve diagnostic precision and uncover novel autoimmune biomarkers.
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Identifying urine DNA methylation signatures as a non-invasive biomarker for lupus nephritis class and disease progression.
Profiling immune responses in severe asthma patients before and after biologic treatment to identify biomarkers of response and novel drug targets.
Using temporal graph machine learning and deep immune profiling to predict which cancer immunotherapy patients will develop autoimmune adverse events before they occur.
